Seed Investment

Biohabit are developing a salivary test for the diagnosis of heart failure, which hopes to replace the need for existing blood tests.  By developing a test that is readily available in multiple healthcare settings, the company are aiming to reduce the time to diagnosis and reducing the costs involved for healthcare services. This has the added benefit of being able to better triage care for patients at the earliest available opportunity and better monitor disease progression.

Cardiovascular diseases are on the rise and heart failure is an ever-increasing problem in our ageing population; by reducing the barriers to disease diagnosis, Biohabit will be able to both serve this market, and open up new avenues for self-care and closer patient management.

Our Approach

What do we look for?

Our business is about forming long term relationships with exceptional entrepreneurs and becoming a trusted partner and supportive investor.

We look for companies with both the vision and potential to become ‘game changers’ and market leaders across a range of sectors.

learn more

Our Team

Rob Carroll

view complete team

Contact us

Binder House
7 Narborough Wood Park
Desford Road
LE19 4XT

Tel: 0116 238 8200